CE Mark for STJ's ILUMIEN OPTIS - Analyst Blog
17 Mayo 2013 - 8:50AM
Zacks
Medical devices major, St. Jude Medical Inc.
(STJ) has won CE Mark approval for its ILUMIEN OPTIS Percutaneous
Coronary Intervention (PCI) Optimization System. This intravascular
imaging technology is an advanced version of the company’s Ilumien
System from the cardiovascular products portfolio, which is used to
treat coronary artery disease.
The ILUMIEN OPTIS System, featuring the unique Fractional Flow
Reserve (FFR) and Optical Coherence Tomography (OCT) platforms,
provides cardiologists with comprehensive information to take
patient-specific stenting decisions, resulting in better treatment
outcomes. Additionally, the device features a three-dimensional
vessel reconstruction technology coupled with a unique stent
planning software tool, which further enhances diagnostics and
treatment strategies.
In Mar 2013, the company had launched the ILUMIEN OPTIS in
Japan. However, the loss of a Japanese distributor is adversely
affecting St. Jude’s Cardiovascular business of late. Apart from
lower expectations from third-party products distributed in Japan,
management lowered guidance for 2013 on account of the
disappointing 1Q13 results and currency adjustments. The company
now expects the Cardiovascular segment to grow 3%–5% (earlier
6%–9%) on a constant currency basis in 2013 on the back of a change
in sales mix from declining legacy products to high growth
offerings.
St. Jude is aggressively working toward improving its declining
top-line performance on the back of new offerings. We believe that
the CE Mark of the new ILUMIEN OPTIS device should add to total
sales in the European Union, given its cutting-edge features.
Recently, the company also received CE Mark approval for its
Ellipse ICDs with SJM Assura CRT-Ds, Allure Quadra CRT-P as well as
for its Brio Libra and LibraXP deep brain stimulation (“DBS”)
product line.
St. Jude currently has a Zacks Rank #3 (Hold). While we remain
on the sidelines regarding STJ, as its core CRM division is still
underperforming, other medical stocks such as
Conceptus (CPTS), Myriad Genetics
(MYGN) and AtriCure (ATRC) warrant a look. While
Conceptus and Myriad carry a Zacks Rank #1 (Strong Buy), ATRC
carries a Zacks Rank #2 (Buy).
ATRICURE INC (ATRC): Free Stock Analysis Report
CONCEPTUS INC (CPTS): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024